This model offers a therapeutic strategy to suppress the STAT3-mediated tumor survival effect in prostate cancer cells that is associated with TLR9 stimulation alongside boosting the antitumor immunity to skew the TLR9 activation response in favor of tumor killing. This evidence concerns the gene STAT3 and neoplasm.